Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
decitabine/ tetrahydrouridine (EPI01)
i
Other names:
EPI01, EPI 01, NN7533, NN 7533, Eclipse, NDec
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
EpiDestiny, Novo Nordisk
Drug class:
Cytidine deaminase inhibitor, DNA methylation inhibitor
Related drugs:
‹
decitabine/cedazuridine (10)
ASTX030 (0)
TdCyd (4)
DNA methyltransferase inhibitor (0)
recombinant methionine α, γ-lyase (0)
decitabine/cedazuridine (10)
ASTX030 (0)
TdCyd (4)
DNA methyltransferase inhibitor (0)
recombinant methionine α, γ-lyase (0)
›
Associations
(1)
News
Trials
Filter by
Latest
6ms
A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People (clinicaltrials.gov)
P1, N=48, Recruiting, Novo Nordisk A/S | Not yet recruiting --> Recruiting
6 months ago
Enrollment open
|
decitabine/ tetrahydrouridine (EPI01)
9ms
A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People (clinicaltrials.gov)
P1, N=48, Not yet recruiting, Novo Nordisk A/S
9 months ago
New P1 trial
|
decitabine/ tetrahydrouridine (EPI01)
12ms
ASCENT1: Research Study Investigating How Well NDec Works in People With Sickle Cell Disease (clinicaltrials.gov)
P2, N=84, Recruiting, Novo Nordisk A/S | Trial primary completion date: Nov 2023 --> Oct 2024
12 months ago
Trial primary completion date
|
hydroxyurea • decitabine/ tetrahydrouridine (EPI01)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login